I’m Hsiang-Wen Tseng, the Vice President of Preclinical Testing Center at Level Biotechnology Inc. I am responsible for maintenance of the contract research organizations (CRO) preclinical services under the GLP regulation and animal facility under IACUC/AAALAC guidelines in Level Biotech. I received the Bachelor of Pharmacy at Taipei Medical University and obtained the Master and Ph.D. degrees from Institute of Pharmacology, National Yang-Ming University. I also have a pharmacist license in Taiwan. My master thesis studied the vasorelaxing mechanisms of anti-hypertensive candidate drug and Ph.D. dissertation was establishment the systems biology platforms (transcriptomics, proteomics, and bioinformatics) to study the LPS-induced inflammation responses. I completed postdoctoral training at Institute of Biological Chemistry in Academia Sinica and as Adjunct Assistant Professor of Biological Chemistry Course at Department of Life Science in National Taiwan Normal University. My majors and specialties are the focus on preclinical disease animal models for more than 20 years of experience in pharmacology and toxicology evaluation of drug development. From 2008 to 2016, I was the Researcher/Senior Researcher and Manager of the Pharmacodynamics Development and Animal Laboratory (AAALAC International Accreditation and ISO/IEC 17025/TAF17025 Accreditation) in Industrial Technology Research Institute (ITRI), the world’s top R&D institutes for developing and commercializing advanced technologies in Taiwan. My department had a total of more than 30 research staffs and provide the preclinical study of in vitro/in vivo of pharmacology and toxicology study for NCE (new chemical entity), drug delivery and nanoparticles, herbs drugs, protein drugs, and ADC (antibody-drug conjugates) projects in ITRI. I also developed many oncology models of human cancer cell lines and patient-derived xenograft (PDX) subcutaneous and orthotopic xenograft models and murine allograft tumor models. In addition, I also established many alternative non-animal in vitro methods and developed a novel in vitro method of skin sensitization for toxicology assay of cosmetics and chemicals. From 2016-2018, I am the Director of preclinical Development at APRINOIA Therapeutics Inc. and responsible to develop and supervise the CRO companies and in-house in vivo study of neurodegeneration disease (Alzheimer’s disease, Parkinson disease, glaucoma and brain traumatic injury) animal models for the pipeline candidate drugs (PET tracer, NCE, and monoclonal antibody) efficacy evaluation. In Level Biotechnology Inc., I am responsible to maintain the contract research organizations (CRO) preclinical services under the TFDA/OECD/USFDA GLP regulation and animal facility under IACUC/AAALAC guidelines for New entity chemical (NEC), biopharmaceutics, medical device, and other related products. Honors: The 13th National Innovation Award/國家新創獎 (2016): Precision Medicine: Novel Conjugation Linker Antibodies-Drug Conjugation Drug The 10th National Innovation Award/國家新創獎 (2013): New Polymer Nano-micelle Technology for Anticancer Drug.